The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo [2,3-b] pyridine-3-carbonyl-2,4-difluoro-phenyl]-amide}, or a pharmaceutically acceptable salt thereof, and an interferon for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the interferon is peginterferon alfa-2a and the disorder is melanoma containing the V600E b-Raf mutation.本發明係關於丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基-2,4-二氟-苯基]-醯胺}或其醫藥學上可接受之鹽及干擾素之組合療法,其係用於治療罹患增生性病症、特別是實體腫瘤(例如結腸直腸癌、黑色素瘤及甲狀腺癌)之患者。特別地,本發明係關於該療法,其中該干擾素為聚乙二醇化干擾素α-2a(peginterferon alfa-2a)且該病症為含有V600E b-Raf突變之黑色素瘤。(無元件符號說明)
